Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Talaulikar, Dipti ^a,b   Shadbolt, Bruce ^a,b   Dahlstrom, Jane E ^a,b   McDonald, Anne ^c  

^a CANBERRA HOSPITAL   (Australia)

^b Canberra Hospital   (Australia)

^c National Capital Private Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; BONE MARROW EXAMINATION; DIAGNOSTIC TEST; EVALUATION; HOSPITAL MANAGEMENT; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANCILLARY SERVICES, HOSPITAL; BONE MARROW EXAMINATION; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 72449156159     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-49     Document Type: Article

References (36)

1. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman, et al. J Clin Oncol 1999 17 12 3835 49 10577857
2. State-of-the-art therapeutics: diffuse large B-cell lymphoma. B Coiffier, J Clin Oncol 2005 23 26 6387 93 10.1200/JCO.2005.05.015 16155024
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. MA Shipp DP Harrington JR Anderson JO Armitage G Bonadonna G Brittinger F Cabanillas GP Canellos B Coiffier JM Connors RA Cowan D Crowther S Dahlberg M Engelhard RI Fisher C Gisselbrecht SJ Horning E Lepage TA Lister JH Meerwald E Montserrat NI Nissen MM Oken BA Peterson C Tondini WA Velasquez BY Yeap, N Engl J Med 1993 329 14 987 94 10.1056/NEJM199309303291402 8141877
4. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. AA Alizadeh MB Eisen RE Davis C Ma IS Lossos A Rosenwald, et al. Nature 2000 403 6769 503 11 10.1038/35000501 10676951
5. Emerging prognostic factors in diffuse large B cell lymphoma. RD Gascoyne, Curr Opin Oncol 2004 16 5 436 41 10.1097/00001622-200409000-00004 15314511
6. Prognostic biomarkers in diffuse large B-cell lymphoma. IS Lossos D Morgensztern, J Clin Oncol 2006 24 6 995 1007 10.1200/JCO.2005.02.4786 16418498
7. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize, et al. N Engl J Med 1993 328 14 1002 6 10.1056/NEJM199304083281404 7680764
8. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. P Sonneveld M de Ridder H van der Lelie K Nieuwenhuis H Schouten A Mulder, et al. J Clin Oncol 1995 13 10 2530 9 7595704
9. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. G Lambertenghi Deliliers C Butti L Baldini A Ceriani F Lombardi M Luoni, et al. Haematologica 1995 80 4 318 24 7590500
10. ICE - an efficient drug combination for stem cell mobilization and high-dose treatment of malignant lymphoma. D Kingreen J Beyer S Kleiner S Reif D Huhn W Siegert, Eur J Haematol Suppl 2001 64 46 50 11486402
11. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. P Goss R Burkes L Rudinskas M King W Chow R Myers, et al. Leuk Lymphoma 1995 18 1-2 145 52 8580817
12. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results. HM Khaled ZK Zekri N Mokhtar NM Ali T Darwish I Elattar, et al. Ann Oncol 1999 10 12 1489 92 10.1023/A:1008395014398 10643541
13. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. SW Lane J Crawford M Kenealy G Cull JF Seymour HM Prince, et al. Leuk Lymphoma 2006 47 9 1813 7 10.1080/10428190600632832 17064993
14. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). PC O'Brien DE Roos KH Liew GE Trotter MB Barton QJ Walker, et al. Med J Aust 1996 165 8 424 7 8913243
15. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. PL Zinzani M Martelli M Magagnoli E Pescarmona L Scaramucci F Palombi, et al. Blood 1999 94 10 3289 93 10552937
16. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors, et al. J Clin Oncol 1999 17 4 1244 10561185
17. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. CA Hanson PJ Kurtin JA Katzmann JD Hoyer CY Li JM Hodnefield, et al. Blood 1999 94 11 3889 96 10572105
18. Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas. A Chadburn DM Knowles, Am J Clin Pathol 1994 102 3 284 91 8085550
19. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. JJ van Dongen AW Langerak M Bruggemann PA Evans M Hummel FL Lavender, et al. Leukemia 2003 17 12 2257 317 10.1038/sj.leu.2403202 14671650
20. A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. H Liu AJ Bench CM Bacon K Payne Y Huang MA Scott, et al. Br J Haematol 2007 138 1 31 43 10.1111/j.1365-2141.2007.06618.x 17555445
21. Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test? MJ Naughton JL Hess MM Zutter NL Bartlett, Cancer 1998 82 6 1154 9 10.1002/(SICI)1097-0142(19980315)82:6<1154::AID-CNCR213.0.CO;2-4 9506363
22. Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry: correlation with morphology. PR Duggan D Easton J Luider IA Auer, Cancer 2000 88 4 894 9 10.1002/(SICI)1097-0142(20000215)88:4<894::AID- CNCR213.0.CO;2-O 10679660
23. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. C Palacio G Acebedo M Navarrete C Ruiz-Marcellan C Sanchez A Blanco, et al. Haematologica 2001 86 9 934 40 11532621
24. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. SP Sah E Matutes AC Wotherspoon R Morilla D Catovsky, J Clin Pathol 2003 56 2 129 32 10.1136/jcp.56.2.129 12560392
25. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). G Perea A Altes M Bellido A Aventin R Bordes R Ayats, et al. Histopathology 2004 45 3 268 74 10.1111/j.1365-2559.2004.01937.x 15330805
26. Immunohistochemistry in apparently normal bone marrow trephine specimens from patients with nodal follicular lymphoma. R Chetty G Echezarreta M Comley K Gatter, J Clin Pathol 1995 48 11 1035 8 10.1136/jcp.48.11.1035 8543627
27. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. M Fraga P Brousset D Schlaifer C Payen A Robert H Rubie, et al. Am J Clin Pathol 1995 103 1 82 9 7817951
28. Correlation of PCR-detected clonal gene rearrangements with bone marrow morphology in patients with B-lineage lymphomas. JE Coad DJ Olson DR Christensen TA Lander R Chibbar RC McGlennen, et al. Am J Surg Pathol 1997 21 9 1047 56 10.1097/00000478-199709000-00009 9298881
29. Morphologic, immunophenotypic, and molecular evaluation of bone marrow involvement in non-Hodgkin's lymphoma. PL Crotty BR Smith G Tallini, Diagn Mol Pathol 1998 7 2 90 5 10.1097/00019606-199804000-00005 9785007
30. Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma. YH Kang CJ Park EJ Seo J Huh SB Kim YK Kang, et al. Cancer 2002 94 12 3073 82 10.1002/cncr.10584 12115337
31. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). G Mitterbauer-Hohendanner C Mannhalter K Winkler M Mitterbauer C Skrabs A Chott, et al. Leukemia 2004 18 6 1102 7 10.1038/sj.leu.2403376 15085149
32. A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. D Talaulikar JX Gray B Shadbolt M McNiven JE Dahlstrom, J Clin Pathol 2008 61 1 119 23 10.1136/jcp.2006.045294 17545562
33. Application of BIOMED-2 primers in fixed and decalcified bone marrow biopsies: analysis of immunoglobulin H receptor rearrangements in B-cell non-Hodgkin's lymphomas. S Lassmann UV Gerlach K Technau-Ihling M Werner P Fisch, J Mol Diagn 2005 7 5 582 91 16258156
34. FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. B Espinet B Bellosillo C Melero MC Vela C Pedro M Salido, et al. Leuk Res 2008 32 5 737 42 10.1016/j.leukres.2007.09.010 17964648
35. Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. SK Juneja MM Wolf IA Cooper, J Clin Pathol 1990 43 8 630 2 10.1136/jcp.43.8.630 2401730
36. How reliable is histologic examination of bone marrow trephine biopsy specimens for the staging of non-Hodgkin lymphoma? A study of hairy cell leukemia and mantle cell lymphoma involvement of the bone marrow trephine specimen by histologic, immunohistochemical, and polymerase chain reaction techniques. S Pittaluga A Tierens YL Dodoo J Delabie C De Wolf-Peeters, Am J Clin Pathol 1999 111 2 179 84 9930138